SAVA Alert: Berman Tabacco Investigates Cassava Sciences, Inc. for Potential Securities Claims in Connection with FDA Citizen Petition

Boston, Massachusetts--(Newsfile Corp. - August 26, 2021) -  Berman Tabacco, a national law firm representing investors, is investigating potential securities law violations by Cassava Sciences, Inc. ("Cassava" or the "Company") (NASDAQ: SAVA), a drug development company.

On August 25, 2021, Bloomberg reported that shares of Cassava were down 31% "after a lawyer sought to stop studies of the biotech company's experimental treatment for Alzheimer's disease." According to Bloomberg, "a citizen petition from a former Securities and Exchange Commission enforcement lawyer questioned the quality and integrity of the results from the more than 20-year-old company with no products on the market." Further, "[t]e FDA says it is reviewing the petition and will respond directly to the petitioner." Shares of Cassava closed at $80.86 per share, down from its close of $117.83 per share on August 24, on heavy volume.

On August 26, 2021, shares Cassava traded down another 13% to approximately $70.18 per share by the midday.

If you purchased Cassava securities, sustained substantial losses and would like more information about the investigation, or have information concerning this investigation, please click here: Shareholder Contact | Berman Tabacco.

Berman Tabacco is a national law firm representing institutions and individuals in lawsuits, seeking to recoup losses caused by corporate and board misconduct and violations of the securities and antitrust laws. The firm has offices in Boston, Massachusetts and San Francisco, California.

This notice may constitute attorney advertising.

Contact:

Jay Eng, Esq.
(800) 516-9926
Email: law@bermantabacco.com

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/94555